2025 catalysts: Bispecifics poised to enter new era

Of all the clinical catalysts on the agenda for 2025, results from bispecific antibody trials could have the broadest impact, with the readouts spanning an array of diseases and therapeutic mechanisms well beyond T cell engagement. 

BioCentury’s analysis of the clinical and regulatory catalysts expected in 2025 identifies bispecific antibodies as one of the year’s breakout trends. Although anchored in highly anticipated data from a global Phase III study of ivonescimab from Akeso Inc. (HKEX:9926) and Summit Therapeutics Inc. (JASDAQ:SMMT), bispecific programs are fanning out across indications, targets and molecule designs that could finally see the modality have its moment — a decade after the first approval. ...